KWM
IMRX icon

Kingsview Wealth Management’s Immuneering IMRX Stock Holding History

Kingsview Wealth Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$614K Buy
123,000
+800
+0.7% +$4.05K 0.01% 903
2026
Q1 		$644K Buy
122,200
+3,600
+3% +$18.5K 0.01% 817
2025
Q4 		$780K Buy
118,600
+28,600
+32% +$184K 0.01% 705
2025
Q3 		$630K Buy
90,000
+76,000
+543% +$394K 0.01% 733
2025
Q2 		$47.2K Buy
+14,000
New +$24K ﹤0.01% 1152

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Kingsview Wealth Management's IMRX Position: Q2 2026 in Review

Kingsview Wealth Management increased its Immuneering (IMRX) stake by 0.65% in Q2 2026, buying an estimated $4.05K and bringing the position to 123,000 shares worth $614K. The position accounts for 0.01% of the portfolio, ranked #903.

Kingsview Wealth Management first reported a position in IMRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $780K in Q4 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Kingsview Wealth Management held 123,000 shares of Immuneering worth $614K as of Q2 2026.
  • Kingsview Wealth Management bought 800 Immuneering shares in Q2 2026, an estimated $4.05K.
  • Immuneering made up 0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #903 holding.
  • Kingsview Wealth Management first reported a position in Immuneering in Q2 2025 and has held it in 5 quarters since.
  • Kingsview Wealth Management's Immuneering position peaked at $780K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.